Heart Failure Clinical Trials

148 studies are recruiting for heart failure in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies now recruiting

1. Alleviant ALLAY-HFrEF Study

   Prospective, multicenter, randomized, sham-controlled, double blind (patient and observer), study designed to evaluate the safety and efficacy of a percutaneously created interatrial shunt using the Alleviant ALV1 System in patients with HFrEF.

   Stage

   Not phased

   Ages

   18 and older

   Site

   Keck Medical Center of USC, Los Angeles, California

   Locations

   68 in total

   Run by

   Alleviant Medical, Inc.

   See if you can join NCT06812533 on ClinicalTrials.gov

2. Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin

   Participants include men and women ≥ 40 years of age with T2DM, established CV disease, a history of HTN with an SBP of at least 130 mmHg at screening, who meet the predefined serum potassium level, and with at least one additional risk factor for HF. The study will include an optional pre-screenin…

   Stage

   Phase 3

   Ages

   40 and older

   Site

   Research Site, Birmingham, Alabama

   Locations

   957 in total

   Run by

   AstraZeneca

   See if you can join NCT06677060 on ClinicalTrials.gov

3. Barostim-Enabled NEurohormonal Intervention For Improving Treatment of Heart Failure

   The purpose of BENEFIT-HF is to demonstrate the safety and effectiveness of Baroreflex Activation Therapy (BAT) with the Barostim System in participants with heart failure, defined as NYHA Functional Class II or III, LVEF < 50% and NT-proBNP < 5,000 pg/mL despite being treated with Guideline-Direct…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Cardiology Associates of Mobile, Mobile, Alabama

   Locations

   11 in total

   Run by

   CVRx, Inc.

   See if you can join NCT07232030 on ClinicalTrials.gov

4. A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients

   Finerenone will be compared to placebo to determine efficacy and safety of treatment in patients hospitalized with acute decompensated heart failure (HF) and mildly reduced or preserved left ventricular ejection fraction.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Birmingham, AL Investigative Site 10012, Birmingham, Alabama

   Locations

   356 in total

   Run by

   Colorado Prevention Center

   See if you can join NCT06008197 on ClinicalTrials.gov

5. A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF)

   Combination therapy of finerenone plus empagliflozin will be compared to usual care to determine the efficacy and safety of treatment in patients hospitalized with heart failure.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   CON-10004 Fairhope, AL Investigational Site, Fairhope, Alabama

   Locations

   140 in total

   Run by

   Colorado Prevention Center

   See if you can join NCT06024746 on ClinicalTrials.gov

6. The WiSE®-UP Study (The WiSE System Utilization & Performance Study)

   Observe to understand product performance, including patient safety, clinical outcomes, and CRT response information associated with the use of the market-released WiSE System

   Stage

   Not phased

   Ages

   22 and older

   Site

   Honor Health, Scottsdale, Arizona

   Locations

   12 in total

   Run by

   EBR Systems, Inc.

   See if you can join NCT07098858 on ClinicalTrials.gov

7. Investigation of the BrioVAD System for the Treatment of Left Ventricular Heart Failure

   The goal of this study is to evaluate the safety and efficacy of the BrioVAD System by demonstrating non-inferiority to the HeartMate 3 Left Ventricular Assist System when used for the treatment of advanced, refractory, left ventricular heart failure.

   Stage

   Not phased

   Ages

   18 to 100

   Site

   University of Alabama at Birmingham Hospital, Birmingham, Alabama

   Locations

   47 in total

   Run by

   BrioHealth Solutions, Inc.

   See if you can join NCT06310031 on ClinicalTrials.gov

8. Mechanisms of Diuretic Resistance in Heart Failure, Aim 2

   Randomized placebo-controlled, double-blind, double-dummy, crossover design testing combinations placebo/placebo, bendroflumethiazide/placebo, amiloride/placebo, and bendroflumethiazide/amiloride added to bumetanide.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Yale University, New Haven, Connecticut

   Run by

   Yale University

   See if you can join NCT05753059 on ClinicalTrials.gov

9. A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart

   This study is open to adults with chronic heart failure (HF) who have a reduced left ventricular ejection fraction (LVEF) of less than 40%. People can join the study if they have been diagnosed with chronic HF at least 3 months before they start on the study. The purpose of this study is to find ou…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Valley Clinical Trials, Inc., Covina, California

   Locations

   588 in total

   Run by

   Boehringer Ingelheim

   See if you can join NCT06935370 on ClinicalTrials.gov

10. Prevalence and Prediction of ATTR in Ambulatory Patients With HFpEF

    Recent studies have shown that transthyretin amyloidosis (ATTR) can sometimes cause a type of heart failure where the pumping function of the heart is normal, also known as Heart Failure with Preserved Ejection Fraction (HFpEF) or diastolic heart failure. In this single center diagnostic study, we …

    Stage

    Not phased

    Ages

    65 and older

    Site

    Massachusetts General Hospital, Boston, Massachusetts

    Run by

    Massachusetts General Hospital

    See if you can join NCT05577819 on ClinicalTrials.gov

11. Targeted Artificial Intelligence Language mOdel Recommendations for Heart Failure (TAILOR-HF)

    This study is an investigator-initiated, cluster-randomized implementation trial evaluating a large language model (LLM)-based clinical decision support (CDS) tool designed to improve guideline-directed medical therapy (GDMT) for adult patients with heart failure seen in outpatient cardiology clini…

    Stage

    Not phased

    Ages

    18 to 85

    Site

    Mass General Brigham, Boston, Massachusetts

    Run by

    Brigham and Women's Hospital

    See if you can join NCT07337577 on ClinicalTrials.gov

12. Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)

    This study aims to compare the efficacy of vericiguat versus placebo on change in n-terminal pro-brain natriuretic peptide (NTproBNP) from baseline to Week 16 of the Base Period. The primary hypothesis is that vericiguat is superior to placebo in reducing NT-proBNP at Week 16 of the Base Period.

    Stage

    Phase 2

    Ages

    0 to 17

    Site

    The Regents of the University of California - Los Angeles (UCLA Pediatrics) ( Site 0002), Los Angeles, California

    Locations

    109 in total

    Run by

    Merck Sharp & Dohme LLC

    See if you can join NCT05714085 on ClinicalTrials.gov

13. Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction

    The purpose of this study is to find out if the investigational drug called omecamtiv mecarbil can reduce the risk of the effects of heart failure, like hospitalization, transplantation, or death in patients with heart failure and severely reduced ejection fraction.

    Stage

    Phase 3

    Ages

    18 to 85

    Site

    Advanced Cardiovascular, LLC, Alexander City, Alabama

    Locations

    205 in total

    Run by

    Cytokinetics

    See if you can join NCT06736574 on ClinicalTrials.gov

14. Optimizing Heart Failure Therapies Among Patients With Limited Access in Denver

    Numerous pharmacotherapies have been proven to reduce mortality and hospitalization rates for heart failure with reduced ejection fraction (HFrEF) patients. However, these are underutilized clinically, preventing realization of proven benefits. Simplified patient education tools and multidisciplina…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Denver Health and Hospital Authority, Denver, Colorado

    Run by

    Denver Health and Hospital Authority

    See if you can join NCT07435662 on ClinicalTrials.gov

15. Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure

    Aortix is a circulatory support device for chronic heart failure patients on medical management who have been hospitalized for acute decompensated heart failure (ADHF) and have persistent congestion despite usual medical therapy. Eligible ADHF patients with diuretic resistance (irrespective of ejec…

    Stage

    Not phased

    Ages

    21 and older

    Site

    Banner--University Medical Center Phoenix, Phoenix, Arizona

    Locations

    50 in total

    Run by

    Procyrion

    See if you can join NCT05677100 on ClinicalTrials.gov

16. NORM-HF Pivotal Study

    This is an international, multi-center, prospective, randomized, open-label blinded endpoint study designed to demonstrate that use of the FIRE1 NORM™ System in the management of New York Heart Association Class II/III HF patients is superior for reducing the combined endpoint of worsening HF event…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Cardiovascular Institute of San Diego, Chula Vista, California

    Locations

    9 in total

    Run by

    Foundry Innovation & Research 1, Limited (FIRE1)

    See if you can join NCT07574593 on ClinicalTrials.gov

17. Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)

    The study investigators are interested in learning more about how drugs, that are given to children by their health care provider, act in the bodies of children and young adults in hopes to find the most safe and effective dose for children. The primary objective of this study is to evaluate the PK…

    Stage

    Not phased

    Ages

    0 to 20

    Site

    Lucile Packard Children's Hospital, Palo Alto, California

    Locations

    52 in total

    Run by

    Duke University

    See if you can join NCT04278404 on ClinicalTrials.gov

18. A Preliminary Study for INFORMED

    Investigators will determine whether N-of-1 trials, as a pragmatic, participant-centered approach to medication optimization that can overcome key barriers of deprescribing, can lead to increased participant confidence regarding their preference to continue or discontinue beta-blockers in older adu…

    Stage

    Phase 4

    Ages

    65 and older

    Site

    Weill Cornell Medicine, New York, New York

    Run by

    Weill Medical College of Cornell University

    See if you can join NCT05585125 on ClinicalTrials.gov

19. Improving TRansitions ANd OutcomeS for Heart FailurE Patients in Home Health CaRe (I-TRANSFER-HF)

    This study is trying to improve the hospital-to-home transition for people with heart failure who receive home care services. The study will test an intervention called I-TRANSFER-HF, which differs from usual care by combining early home health nurse visits and outpatient medical appointments. The …

    Stage

    Not phased

    Ages

    18 and older

    Site

    VNS Health Partners in Care, New York, New York

    Locations

    2 in total

    Run by

    Weill Medical College of Cornell University

    See if you can join NCT06118983 on ClinicalTrials.gov

20. A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure

    This study is open to adults aged 18 or above legal age with heart failure. People can join the study if they have heart failure symptoms and a left ventricular ejection fraction (LVEF) of 40% or more. The purpose of this study is to find out whether vicadrostat (BI 690517) in combination with empa…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Diagnostic and Medical Clinic, Mobile, Alabama

    Locations

    652 in total

    Run by

    Boehringer Ingelheim

    See if you can join NCT06424288 on ClinicalTrials.gov

21. A Study of LY3971297 in Participants With Heart Failure

    The main purpose of this study is to assess how well LY3971297 is tolerated and what side effects may occur in participants with heart failure with preserved ejection fraction (HFpEF) and participants with heart failure with reduced ejection fraction (HFrEF). Blood tests will be performed to invest…

    Stage

    Phase 1

    Ages

    18 to 65

    Site

    Republican Clinical Hospital ARENSIA Exploratory Medicine, Chisinau,

    Locations

    12 in total

    Run by

    Eli Lilly and Company

    See if you can join NCT07547540 on ClinicalTrials.gov

22. Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products

    The main purpose of the Product Performance Report (formerly referred to as System Longevity Study) is to evaluate long-term performance of Medtronic market-released cardiac rhythm products by analyzing product survival probabilities.

    Stage

    Not phased

    Ages

    Any age

    Site

    Research site, Birmingham, Alabama

    Locations

    333 in total

    Run by

    Medtronic

    See if you can join NCT00271180 on ClinicalTrials.gov

23. Contrast Echocardiography During Exercise to Assess Pulmonary Blood Volume

    The purpose of this study is to evaluate whether pulmonary blood volume (PBV) derived from contrast echocardiography can serve as a non-invasive surrogate for invasive pulmonary artery wedge pressure (PAWP) during exercise. Also, to compare changes in PBV with exercise in patients with and without …

    Stage

    Not phased

    Ages

    18 and older

    Site

    Mayo Clinic in Rochester, Rochester, Minnesota

    Run by

    Mayo Clinic

    See if you can join NCT06195059 on ClinicalTrials.gov

24. Feasibility and Efficacy Study of the CardioPulmonary Management (CPM) System in Patients With Chronic Heart Failure

    The primary purpose for this study is to support the hypothesis (pilot data) that the use of the Sensinel CPM system reduces the rate of HF-related events and the related healthcare cost. The study will also measure the impact on quality of care and patient satisfaction. In order to support the pri…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Baptist Health South Florida, Miami, Florida

    Locations

    7 in total

    Run by

    Analog Device, Inc.

    See if you can join NCT05650541 on ClinicalTrials.gov

25. Impella Reverse Remodeling in End-Stage Heart Failure

    This observational study is being done to learn more about heart attack recovery in patients supported with the Impella 5.5 left ventricular assist device (LVAD) as part of their standard of care. There are three stages in this study: screening, treatment and post treatment. There will be two phase…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Columbia University, New York, New York

    Run by

    Columbia University

    See if you can join NCT06800716 on ClinicalTrials.gov